Johnson & Johnson Total Current Liabilities 2010-2024 | JNJ
Johnson & Johnson total current liabilities from 2010 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
- Johnson & Johnson total current liabilities for the quarter ending September 30, 2024 were $51.759B, a 16.65% increase year-over-year.
- Johnson & Johnson total current liabilities for 2023 were $46.282B, a 17.06% decline from 2022.
- Johnson & Johnson total current liabilities for 2022 were $55.802B, a 23.38% increase from 2021.
- Johnson & Johnson total current liabilities for 2021 were $45.226B, a 6.43% increase from 2020.
Johnson & Johnson Annual Total Current Liabilities
(Millions of US $) |
| 2023 |
$46,282 |
| 2022 |
$55,802 |
| 2021 |
$45,226 |
| 2020 |
$42,493 |
| 2019 |
$35,964 |
| 2018 |
$31,230 |
| 2017 |
$30,537 |
| 2016 |
$26,287 |
| 2015 |
$27,747 |
| 2014 |
$25,031 |
| 2013 |
$25,675 |
| 2012 |
$24,262 |
| 2011 |
$22,811 |
| 2010 |
$23,072 |
| 2009 |
$21,731 |
Johnson & Johnson Quarterly Total Current Liabilities
(Millions of US $) |
| 2024-09-30 |
$51,759 |
| 2024-06-30 |
$53,933 |
| 2024-03-31 |
$48,725 |
| 2023-12-31 |
$46,282 |
| 2023-09-30 |
$44,370 |
| 2023-06-30 |
$54,170 |
| 2023-03-31 |
$60,373 |
| 2022-12-31 |
$55,802 |
| 2022-09-30 |
$45,543 |
| 2022-06-30 |
$44,821 |
| 2022-03-31 |
$43,390 |
| 2021-12-31 |
$45,226 |
| 2021-09-30 |
$44,561 |
| 2021-06-30 |
$38,721 |
| 2021-03-31 |
$40,932 |
| 2020-12-31 |
$42,493 |
| 2020-09-30 |
$38,847 |
| 2020-06-30 |
$36,772 |
| 2020-03-31 |
$33,689 |
| 2019-12-31 |
$35,964 |
| 2019-09-30 |
$35,162 |
| 2019-06-30 |
$31,353 |
| 2019-03-31 |
$29,111 |
| 2018-12-31 |
$31,230 |
| 2018-09-30 |
$27,437 |
| 2018-06-30 |
$27,488 |
| 2018-03-31 |
$27,081 |
| 2017-12-31 |
$30,537 |
| 2017-09-30 |
$31,806 |
| 2017-06-30 |
$28,872 |
| 2017-03-31 |
$25,119 |
| 2016-12-31 |
$26,287 |
| 2016-09-30 |
$23,230 |
| 2016-06-30 |
$21,536 |
| 2016-03-31 |
$22,134 |
| 2015-12-31 |
$27,747 |
| 2015-09-30 |
$25,260 |
| 2015-06-30 |
$24,512 |
| 2015-03-31 |
$23,836 |
| 2014-12-31 |
$25,031 |
| 2014-09-30 |
$22,982 |
| 2014-06-30 |
$24,359 |
| 2014-03-31 |
$23,840 |
| 2013-12-31 |
$25,675 |
| 2013-09-30 |
$25,835 |
| 2013-06-30 |
$23,767 |
| 2013-03-31 |
$22,524 |
| 2012-12-31 |
$24,262 |
| 2012-09-30 |
$23,935 |
| 2012-06-30 |
$23,848 |
| 2012-03-31 |
$21,198 |
| 2011-12-31 |
$22,811 |
| 2011-09-30 |
$21,686 |
| 2011-06-30 |
$20,985 |
| 2011-03-31 |
$24,011 |
| 2010-12-31 |
$23,072 |
| 2010-09-30 |
$17,414 |
| 2010-06-30 |
$17,164 |
| 2010-03-31 |
$18,499 |
| 2009-12-31 |
$21,731 |
| 2009-09-30 |
$19,245 |
| 2009-06-30 |
$19,886 |
| 2009-03-31 |
$21,325 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$368.366B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
